Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H26O6 |
Molecular Weight | 386.4382 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1
InChI
InChIKey=VWVKUNOPTJGDOB-BDHVOXNPSA-N
InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
Molecular Formula | C22H26O6 |
Molecular Weight | 386.4382 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22889351 |
2.9 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DEBERZA Approved UseThe treatment of type 2 diabetes mellitus. Launch Date2012 |
PubMed
Title | Date | PubMed |
---|---|---|
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. | 2012 Jun |
|
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. | 2012 Sep 13 |
|
In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. | 2013 Apr |
|
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. | 2013 Feb 15 |
Patents
Sample Use Guides
In general, for adults, take 20 mg of tofogliflozin once a day, before or after breakfast.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26158396
Primary cultured proximal tubular epithelial cells from human normal kidney were treated with or without 3 nM or 30 nM tofogliflozin and with or without 22.8 mM glucose. Tofogliflozin dose-dependently suppressed glucose entry into tubular cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:47:53 GMT 2023
by
admin
on
Fri Dec 15 19:47:53 GMT 2023
|
Record UNII |
554245W62T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98083
Created by
admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
554245W62T
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
903565-83-3
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
C152676
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
SUB177215
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
46908929
Created by
admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
|
PRIMARY | |||
|
DTXSID90238097
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
m11867
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY | |||
|
100000163089
Created by
admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
|
PRIMARY | |||
|
9275
Created by
admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
20.4 EXCRETED IN FECES
MAJOR
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
76% OF TOTAL DOSE EXCRETED IN URINE;
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PERCENT OF TOTAL DOSE
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PERCENT OF AUC
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
TAKEN FROM AUC
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
PERCENT OF TOTAL DOSE
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|